South Korea · Delayed Price · Currency is KRW CG MedTech Statistics
Total Valuation
CG MedTech has a market cap or net worth of KRW 110.59 billion. The enterprise value is 89.80 billion.
| Market Cap | 110.59B |
| Enterprise Value | 89.80B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CG MedTech has 103.26 million shares outstanding. The number of shares has increased by 42.12% in one year.
| Current Share Class | 103.26M |
| Shares Outstanding | 103.26M |
| Shares Change (YoY) | +42.12% |
| Shares Change (QoQ) | +1.18% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | n/a |
| Float | 46.81M |
Valuation Ratios
The trailing PE ratio is 44.10.
| PE Ratio | 44.10 |
| Forward PE | n/a |
| PS Ratio | 2.59 |
| PB Ratio | 1.25 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 89.04 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.83, with an EV/FCF ratio of -127.18.
| EV / Earnings | 35.20 |
| EV / Sales | 2.10 |
| EV / EBITDA | 19.83 |
| EV / EBIT | 33.20 |
| EV / FCF | -127.18 |
Financial Position
The company has a current ratio of 3.57, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.57 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 1.10 |
| Debt / FCF | -7.01 |
| Interest Coverage | 14.48 |
Financial Efficiency
Return on equity (ROE) is 3.16% and return on invested capital (ROIC) is 2.02%.
| Return on Equity (ROE) | 3.16% |
| Return on Assets (ROA) | 1.70% |
| Return on Invested Capital (ROIC) | 2.02% |
| Return on Capital Employed (ROCE) | 2.76% |
| Revenue Per Employee | 356.14M |
| Profits Per Employee | 21.26M |
| Employee Count | 120 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.84 |
Taxes
In the past 12 months, CG MedTech has paid 202.69 million in taxes.
| Income Tax | 202.69M |
| Effective Tax Rate | 7.51% |
Stock Price Statistics
The stock price has decreased by -23.01% in the last 52 weeks. The beta is -0.55, so CG MedTech's price volatility has been lower than the market average.
| Beta (5Y) | -0.55 |
| 52-Week Price Change | -23.01% |
| 50-Day Moving Average | 1,044.88 |
| 200-Day Moving Average | 1,005.57 |
| Relative Strength Index (RSI) | 55.03 |
| Average Volume (20 Days) | 520,415 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CG MedTech had revenue of KRW 42.74 billion and earned 2.55 billion in profits. Earnings per share was 24.29.
| Revenue | 42.74B |
| Gross Profit | 19.43B |
| Operating Income | 2.69B |
| Pretax Income | 2.70B |
| Net Income | 2.55B |
| EBITDA | 4.51B |
| EBIT | 2.69B |
| Earnings Per Share (EPS) | 24.29 |
Balance Sheet
The company has 25.89 billion in cash and 4.95 billion in debt, giving a net cash position of 20.94 billion or 202.76 per share.
| Cash & Cash Equivalents | 25.89B |
| Total Debt | 4.95B |
| Net Cash | 20.94B |
| Net Cash Per Share | 202.76 |
| Equity (Book Value) | 88.31B |
| Book Value Per Share | 853.83 |
| Working Capital | 33.88B |
Cash Flow
In the last 12 months, operating cash flow was 1.24 billion and capital expenditures -1.95 billion, giving a free cash flow of -706.09 million.
| Operating Cash Flow | 1.24B |
| Capital Expenditures | -1.95B |
| Free Cash Flow | -706.09M |
| FCF Per Share | -6.84 |
Margins
Gross margin is 45.46%, with operating and profit margins of 6.29% and 5.97%.
| Gross Margin | 45.46% |
| Operating Margin | 6.29% |
| Pretax Margin | 6.31% |
| Profit Margin | 5.97% |
| EBITDA Margin | 10.56% |
| EBIT Margin | 6.29% |
| FCF Margin | n/a |
Dividends & Yields
CG MedTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.12% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.31% |
| FCF Yield | -0.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 5, 2022. It was a forward split with a ratio of 5.
| Last Split Date | Aug 5, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
CG MedTech has an Altman Z-Score of 3.21 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.21 |
| Piotroski F-Score | 4 |